Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Benoit Tessoulin,Seok-Goo Cho,Michal Taszner,Tae Min Kim,Silvana Novelli,Jose C. Villasboas,Michele Merli,Ana Jimenez Ubieto,Michelle Poon,David Tucker,Jan Walewski,Shuhua Yi,Yuqin Song, Geoffrey Chong,Emmanuel Bachy,Stephanie Guidez,Aranzazu Alonso,Deepa Jagadeesh,Wei Zhang,Laura Magnano, Elzbieta Iskierka-Jazdzewska, Monica Tani, Jessica Cai, Cristina Ivanescu, Matthew Reaney, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, James Harnett, Lei Chi, Stefano Luminari

BLOOD（2023）

引用 0|浏览7

暂无评分

摘要

Background: Goals of patient-centered care for management of relapsed or refractory follicular lymphoma (R/R FL) are to improve clinical outcomes while maintaining or improving health-related quality of life (HRQoL). In ELM-2 (NCT03888105), a Phase 2, open-label, multicohort, multicenter study, odronextamab monotherapy demonstrated high and durable complete response rates and generally manageable safety in patients with R/R FL. We report here, for the first time, patient-reported outcome (PRO) results from ELM-2 in patients with R/R FL.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要